Dae Zang

Publications (2)5.67 Total impact

• Article: Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer.

  Dae Young Zang, Dae Hyun Yang, Min-Jeong Kim, Kyung Mi Jang, Se Won Hwang, Kyo-Sang Yoo, Taeho Han, Ho Young Kim, Hyo Jung Kim, Jung Hye Kwon, Hun Ho Song, Sarah Park, Joo Young Jung, Hyeong Su Kim, Jung Han Kim
  [show abstract] [hide abstract]
  ABSTRACT: To determine the maximum tolerated dose (MTD), recommended dose (RD), and activity of combined docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy on metastatic gastric cancer. Docetaxel and oxaliplatin were administered intravenously on day 1 and S-1 was administered orally on days 1-14 of every 21-day cycle. The doses of docetaxel/oxaliplatin/S-1 in the phase I study were level -1A, 52.5/80/60 mg/m(2); level -1B, 52.5/80/80 mg/m(2); level 1A, 52.5/105/80 mg/m(2); level 1B, 52.5/130/80 mg/m(2); level 2A, 60/105/80 mg/m(2); level 2B, 60/130/80 mg/m(2); level 3A, 67.5/105/80 mg/m(2); level 3B, 67.5/130/80 mg/m(2); level 4A, 75/105/80 mg/m(2); level 4B, 75/130/80 mg/m(2). Nine patients were enrolled. One of six patients at level 1A and two of three patients at level 1B developed dose-limiting toxicity (febrile neutropenia) during the initial two cycles. Therefore, the doses used at levels 1B and 1A were defined as the MTD and RD, respectively. All patients were evaluated for toxicity and response. Six partial responses were noted, and the overall response rate was 67%. The RD of the DOS regimen in patients with advanced gastric cancer was docetaxel 52.5 mg/m(2) and oxaliplatin 105 mg/m(2) on day 1 and S-1 80 mg/m(2) on days 1-14 of every 21-day cycle. A phase II study using the RD is currently underway.
  Cancer Chemotherapy and Pharmacology 03/2009; 64(5):877-83. · 2.83 Impact Factor
• Article: Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with consideration to age.

  Dae Young Zang, Dae Hyun Yang, Hae Wan Lee, Se Won Hwang, Hun Ho Song, Joo Young Jung, Jung Hye Kwon, Hyo Jung Kim, Jung Han Kim, Sa Rah Park, Min-Jeong Kim, Kyung Mi Jang, Choong Kee Park, Jong Hyeok Kim, Bong Hwa Lee
  [show abstract] [hide abstract]
  ABSTRACT: To determine the dose-limiting toxicity (DLT) and activity of combination with docetaxel and S-1 on unresectable gastric cancer. Docetaxel was administered intravenously on day 1 and S-1 was administered orally on days 1-14, every 3 weeks. Doses of each drug in phase I study were docetaxel 60-75 mg/m(2) and S-1 60-80 mg/m(2). A phase II study was conducted with the recommended dose (RD) based on phase I. Sixty-five patients (median age 54 years) were enrolled. The DLTs were neutropenia with fever or stomatitis. The RD was docetaxel 75 mg/m(2) and S-1 60 mg/m(2). Two patients (aged 66 and 64 years) developed septic shock during the initial part of phase II study. A phase I study at lower dose (docetaxel 60 mg/m(2) and S-1 80 mg/m(2)) was conducted for patients older than 60 years, and this dose was determined as the RD for these patients. In the phase II study, frequent grade 3/4 toxicities were neutropenia (47%) and febrile neutropenia (26%). The overall response rate was 50% (95% CI, 35-66%) and median survival was 15.3 months (95% CI, 10.0-20.6 months). Combination with docetaxel and S-1 was active against advanced gastric cancer and gave manageable toxicities.
  Cancer Chemotherapy and Pharmacology 06/2008; 63(3):509-16. · 2.83 Impact Factor